



Hepatitis C Drug Therapy Product Selection Grid

Zepatier™ is the preferred Hepatitis C product for genotypes 1 and 4. Documentation on reason or contraindication must be provided when requesting other products.

Drug Therapy	Cirrhosis	G1a		G1b		G2		G3		G4		G5		G6	
		TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE
Zepatier™	No	12w ^t	12w ^{t1}	12w	12w ¹					12w	12w ^{1a}				
	Comp	12w ^t	12w ^{t1}	12w	12w ¹					12w	12w ^{1a}				
Zepatier™ + RBV	No	16w ^t	12-16w ^{p4} , 16w ^{t1}		12w ⁴						16w ^{1b}				
	Comp	16w ^t	12-16w ^{p4} , 16w ^{t1}		12w ⁴						16w ^{1b}				
Zepatier™ + Sovaldi®	No							12w							
	Comp							12w							
Epclusa®	No	12w	12w ⁵	12w	12w ⁵	12w	12w ¹	12w	12w ¹	12w	12w ¹	12w	12w ¹	12w	12w ¹
	Comp	12w	12w ⁵	12w	12w ⁵	12w	12w ¹	12w		12w	12w ¹	12w	12w ¹	12w	12w ¹
	Decomp	24w	24w	24w	24w					24w	24w				
Epclusa® + RBV	No						12w ²		12w ²						
	Comp						12w ²		12w ^{1,2}						
	Decomp	12w	12w	12w	12w	12w	12w	12w	12w	12w	12w				
Viekira Pak™/XR™	No			12w	12w ¹										
	Comp			12w	12w ¹										
Viekira Pak™/XR™ + RBV	No	12w	12w ¹												
	No & Post Transplant [^]	24w [^]		24w [^]											
	Comp	24w	24w ¹												
Technivie™+ RBV	No									12w	12w ¹				
	Comp									12w	12w ¹				
Harvoni®	No	12w	12w ⁵	12w	12w ⁵					12w	12w ¹	12w	12w ¹	12w	12w ¹
	No & low HCV RNA [*]	8w [*]		8w [*]											
	No & Post Transplant [^]	24w [^]		24w [^]						24w [^]					
	Comp	12w	24w ⁵	12w	24w ⁵					12w	24w ¹	12w	12w ¹	12w	12w ¹



Hepatitis C Drug Therapy Product Selection Grid

Drug Therapy	Cirrhosis	G1a		G1b		G2		G3		G4		G5		G6	
		TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE
Harvoni®	Comp & Post Transplant [^]	24w [^]		24w [^]						24w [^]					
	Decomp	24w	24w	24w	24w					24w	24w				
Harvoni® + RBV	No		12w ³		12w ³										
	No & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]					12w [^]	12w [^]				
	Comp		12w ⁵ , 24w ³		12w ⁵ , 24w ³						12w ¹				
	Comp & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]					12w [^]	12w [^]				
	Decomp	12w	12w ⁵	12w	12w ⁵					12w	12w				
	Decomp & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]					12w [^]	12w [^]				
Sovaldi® + RBV	No & Post Transplant [^]					24w [^]	24w [^]								
	Comp & Post Transplant [^]					24w [^]	24w [^]								
	Decomp & Post Transplant [^]					24w [^]	24w [^]								
Olysio® + Sovaldi®	No	12w	12w ¹	12w	12w ¹										
	No & Post Transplant [^]	12w [^]		12w [^]											
	Comp	24w ⁿ	24w ⁿ¹	24w	24w ¹										
	Comp & Post Transplant [^]	12w [^]		12w [^]											
Daklinza® + Sovaldi®	No	12w	12w ⁵	12w	12w ⁵	12w	12w ¹ , 24w ²	12w	12w ¹						
	No & Post Transplant [^]	24w [^]		24w [^]		24w [^]	24w [^]	24w [^]	24w [^]	24w [^]					
	Comp	24w	24w ⁵	24w	24w ⁵	16- 24w	16-24w ¹ , 24w ²	24w							



Hepatitis C Drug Therapy Product Selection Grid

Drug Therapy	Cirrhosis	G1a		G1b		G2		G3		G4		G5		G6	
		TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE
Daklinza® + Sovaldi®	Comp & Post Transplant [^]	24w [^]		24w [^]		24w [^]	24w [^]	24w [^]	24w [^]	24w [^]					
	Decomp	24w	24w	24w	24w					24w	24w				
Daklinza® + Sovaldi® + RBV	No								24w ²						
	No & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]				
	Comp								24w ^{1,2}						
	Comp & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]				
	Decomp	12w	12w	12w	12w	12w	12w	12w	12w	12w	12w	12w			

^fFor genotype 1a, Zepatier™ should be given alone for 12 weeks in patients without, or with ribavirin for 16 weeks in patients with, NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93.

^pPatients who have NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93 should have treatment extended to 16 weeks.

ⁿOnly for patients who have tested negative for the Q80K variant.

^{*}Harvoni® for 8 weeks may be considered in G1 treatment-naïve patients without cirrhosis who have a pre-treatment HCV RNA < 6 million IU/ml.

[^]For patients who develop HCV infection post-liver transplantation.

¹For patients who have failed pegIFN/RBV.

^{1a}For patients who experienced virologic relapse after prior pegIFN/RBV therapy.

^{1b}For patients who experienced on-treatment virologic failure while on prior pegIFN/RBV therapy.

²For patients who have failed sofosbuvir + RBV.

³For patients who have failed sofosbuvir + RBV +/- pegIFN.

⁴For patients who have failed a NS3 protease inhibitor + pegIFN/RBV.

⁵For patients who have failed pegIFN/RBV +/- a NS3 protease inhibitor.

Key	
TN	Treatment-naïve
TE	Treatment-experienced
Comp	Compensated
Decomp	Decompensated
RBV	Ribavirin
pegIFN	Peginterferon
	Preferred First Line Therapy

References:

- <http://hcvguidelines.org/full-report-view>.
- http://packageinserts.bms.com/pi/pi_daklinza.pdf.
- http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf.
- http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf.
- <http://www.olybio.com/shared/product/olybio/prescribing-information.pdf>.
- http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf.
- http://www.rxabbvie.com/pdf/technivie_pi.pdf.
- http://www.rxabbvie.com/pdf/viekirapak_pi.pdf.
- http://www.rxabbvie.com/pdf/viekiraxr_pi.pdf.
- http://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf.
- http://www.merck.ca/assets/en/pdf/products/ZEPATIER-PM_E.pdf.